{
     "PMID": "27806235",
     "OWN": "NLM",
     "STAT": "MEDLINE",
     "DCOM": "20161213",
     "LR": "20170425",
     "IS": "1533-4406 (Electronic) 0028-4793 (Linking)",
     "VI": "375",
     "IP": "18",
     "DP": "2016 Nov 3",
     "TI": "Acute Neurologic Disorder from an Inhibitor of Fatty Acid Amide Hydrolase.",
     "PG": "1717-1725",
     "AB": "BACKGROUND: A decrease in fatty acid amide hydrolase (FAAH) activity increases the levels of endogenous analogues of cannabinoids, or endocannabinoids. FAAH inhibitors have shown analgesic and antiinflammatory activity in animal models, and some have been tested in phase 1 and 2 studies. In a phase 1 study, BIA 10-2474, an orally administered reversible FAAH inhibitor, was given to healthy volunteers to assess safety. METHODS: Single doses (0.25 to 100 mg) and repeated oral doses (2.5 to 20 mg for 10 days) of BIA 10-2474 had been administered to 84 healthy volunteers in sequential cohorts; no severe adverse events had been reported. Another cohort of participants was then assigned to placebo (2 participants) or 50 mg of BIA 10-2474 per day (6 participants). This report focuses on neurologic adverse events in participants in this final cohort. A total of 4 of the 6 participants who received active treatment consented to have their clinical and radiologic data included in this report. RESULTS: An acute and rapidly progressive neurologic syndrome developed in three of the four participants starting on the fifth day of drug administration. The main clinical features were headache, a cerebellar syndrome, memory impairment, and altered consciousness. Magnetic resonance imaging showed bilateral and symmetric cerebral lesions, including microhemorrhages and hyperintensities on fluid-attenuated inversion recovery and diffusion-weighted imaging sequences predominantly involving the pons and hippocampi. One patient became brain dead; the condition of two patients subsequently improved, but one patient had residual memory impairment, and the other patient had a residual cerebellar syndrome. One patient remained asymptomatic. CONCLUSIONS: An unanticipated severe neurologic disorder occurred after ingestion of BIA 10-2474 at the highest dose level used in a phase 1 trial. The underlying mechanism of this toxic cerebral syndrome remains unknown.",
     "FAU": [
          "Kerbrat, Anne",
          "Ferre, Jean-Christophe",
          "Fillatre, Pierre",
          "Ronziere, Thomas",
          "Vannier, Stephane",
          "Carsin-Nicol, Beatrice",
          "Lavoue, Sylvain",
          "Verin, Marc",
          "Gauvrit, Jean-Yves",
          "Le Tulzo, Yves",
          "Edan, Gilles"
     ],
     "AU": [
          "Kerbrat A",
          "Ferre JC",
          "Fillatre P",
          "Ronziere T",
          "Vannier S",
          "Carsin-Nicol B",
          "Lavoue S",
          "Verin M",
          "Gauvrit JY",
          "Le Tulzo Y",
          "Edan G"
     ],
     "AD": "From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France. From the Departments of Neurology (A.K., T.R., S.V., M.V., G.E.), Radiology (J.-C.F., B.C.-N., J.-Y.G.), and Infectious Diseases and Medical Intensive Care (P.F., S.L., Y.L.T.), Centre d'Investigation Clinique-Plurithematique, INSERM 1414 (P.F., Y.L.T., G.E.), and EA 4712 Comportement et Noyaux Gris Centraux Laboratory (M.V.), Rennes University Hospital, and the Vision, Action, and Information Management System in Health team, Institut National de Recherche en Informatique et en Automatique (A.K., J.-C.F., J.-Y.G.) - all in Rennes, France.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Clinical Trial, Phase I",
          "Journal Article",
          "Randomized Controlled Trial"
     ],
     "PL": "United States",
     "TA": "N Engl J Med",
     "JT": "The New England journal of medicine",
     "JID": "0255562",
     "RN": [
          "0 (BIA 10-2474)",
          "0 (Cyclic N-Oxides)",
          "0 (Pyridines)",
          "EC 3.5.- (Amidohydrolases)",
          "EC 3.5.1.- (fatty-acid amide hydrolase)"
     ],
     "SB": "AIM IM",
     "CIN": [
          "N Engl J Med. 2016 Nov 3;375(18):1788-1789. PMID: 27806239",
          "N Engl J Med. ;376(4):292-3. PMID: 28124888",
          "N Engl J Med. ;376(4):393. PMID: 28124889",
          "N Engl J Med. ;376(4):392. PMID: 28124887",
          "N Engl J Med. 2017 Jan 26;376(4):393-4. PMID: 28121500",
          "N Engl J Med. 2017 Jan 26;376(4):393. PMID: 28121501"
     ],
     "MH": [
          "Acute Disease",
          "Administration, Oral",
          "Adult",
          "Amidohydrolases/*antagonists & inhibitors",
          "Brain Death",
          "Cerebellar Diseases/*chemically induced",
          "Cerebellum/pathology",
          "Cerebral Hemorrhage/chemically induced/diagnosis",
          "Consciousness Disorders/*chemically induced",
          "Cyclic N-Oxides/administration & dosage/*adverse effects",
          "Double-Blind Method",
          "Gait Ataxia/chemically induced",
          "Headache/chemically induced",
          "Healthy Volunteers",
          "Hippocampus/*pathology",
          "Humans",
          "Magnetic Resonance Imaging",
          "Male",
          "Memory Disorders/*chemically induced",
          "Middle Aged",
          "Pons/*pathology",
          "Pyridines/administration & dosage/*adverse effects"
     ],
     "EDAT": "2016/11/03 06:00",
     "MHDA": "2016/12/15 06:00",
     "CRDT": [
          "2016/11/03 06:00"
     ],
     "PHST": [
          "2016/11/03 06:00 [pubmed]",
          "2016/12/15 06:00 [medline]",
          "2016/11/03 06:00 [entrez]"
     ],
     "AID": [
          "10.1056/NEJMoa1604221 [doi]"
     ],
     "PST": "ppublish",
     "SO": "N Engl J Med. 2016 Nov 3;375(18):1717-1725. doi: 10.1056/NEJMoa1604221.",
     "term": "hippocampus"
}